D
Douglas A. Melton
Researcher at Harvard University
Publications - 299
Citations - 73978
Douglas A. Melton is an academic researcher from Harvard University. The author has contributed to research in topics: Stem cell & Cellular differentiation. The author has an hindex of 120, co-authored 291 publications receiving 70103 citations. Previous affiliations of Douglas A. Melton include Broad Institute & Fairchild Semiconductor International, Inc..
Papers
More filters
Journal ArticleDOI
A truncated activin receptor inhibits mesoderm induction and formation of axial structures in Xenopus embryos
TL;DR: A mutant activin receptor that inhibits activin signalling is used to show that activin is required for the induction of mesoderm in vivo and the patterning of the embryonic body plan.
Journal ArticleDOI
Activins are expressed early in Xenopus embryogenesis and can induce axial mesoderm and anterior structures.
Gerald H. Thomsen,Tod M. Woolf,Malcolm Whitman,Sergei Y. Sokol,J. Vaughan,Wylie Vale,Douglas A. Melton +6 more
TL;DR: It is suggested that early induction and axial patterning are accomplished by endogenous activin B, not activin A, in Xenopus, and that ectopic expression of Xenopus activin beta B produces a second body axis in embryos injected with synthetic mRNA.
Journal ArticleDOI
Recovery from diabetes in mice by β cell regeneration
TL;DR: This article developed a transgenic mouse model to study the dynamics of pancreatic β cell regeneration from a diabetic state and found that withdrawal of doxycycline resulted in a spontaneous normalization of blood glucose levels and islet architecture and a significant regeneration of beta cell mass with no apparent toxicity of transient hyperglycemia.
Journal ArticleDOI
Vertebrate endoderm development
James M. Wells,Douglas A. Melton +1 more
TL;DR: Possible mechanisms that regulate how undifferentiated endoderm becomes specified into a myriad of cell types that populate the respiratory and gastrointestinal tracts are discussed.
Journal ArticleDOI
Long-term glycemic control using polymer-encapsulated human stem cell-derived beta cells in immune-competent mice
Arturo J. Vegas,Arturo J. Vegas,Arturo J. Vegas,Omid Veiseh,Omid Veiseh,Mads Gürtler,Jeffrey R. Millman,Felicia W. Pagliuca,Andrew Bader,Andrew Bader,Andrew Bader,Joshua C. Doloff,Joshua C. Doloff,Jie Li,Jie Li,Michael Chen,Michael Chen,Karsten Olejnik,Karsten Olejnik,Hok Hei Tam,Hok Hei Tam,Siddharth Jhunjhunwala,Siddharth Jhunjhunwala,Erin Langan,Erin Langan,Stephanie Aresta-Dasilva,Stephanie Aresta-Dasilva,Srujan Gandham,Srujan Gandham,James J. McGarrigle,Matthew A. Bochenek,Jennifer Hollister-Lock,Jose Oberholzer,Dale L. Greiner,Gordon C. Weir,Douglas A. Melton,Douglas A. Melton,Robert Langer,Daniel G. Anderson +38 more
TL;DR: The first long-term glycemic correction of a diabetic, immunocompetent animal model using human SC-β cells is reported, which induced glycemic Correction without any immunosuppression until their removal at 174 d after implantation.